These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31734621)

  • 21. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
    Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
    CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
    Nygaard GO; Torgauten H; Skattebøl L; Høgestøl EA; Sowa P; Myhr KM; Torkildsen Ø; Celius EG
    Mult Scler Relat Disord; 2022 Jun; 62():103812. PubMed ID: 35462167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What happens after fingolimod discontinuation? A multicentre real-life experience.
    Landi D; Signori A; Cellerino M; Fenu G; Nicoletti CG; Ponzano M; Mancuso E; Fronza M; Ricchiuto ME; Boffa G; Inglese M; Marfia GA; Cocco E; Frau J
    J Neurol; 2022 Feb; 269(2):796-804. PubMed ID: 34136943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy.
    Hellwig K; Tokic M; Thiel S; Hemat S; Timmesfeld N; Ciplea AI; Gold R; Langer-Gould AM
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37217309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.
    Zivadinov R; Medin J; Khan N; Korn JR; Chitnis T; Naismith RT; Alvarez E; Dwyer MG; Bergsland N; Carl E; Silva D; Weinstock-Guttman B;
    Mult Scler Relat Disord; 2019 Jan; 27():65-73. PubMed ID: 30342416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency and risk factors of rebound after fingolimod discontinuation - A retrospective study.
    Maunula A; Atula S; Laakso SM; Tienari PJ
    Mult Scler Relat Disord; 2024 Jan; 81():105134. PubMed ID: 37980790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
    Członkowska A; Smoliński Ł; Litwin T
    Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
    Berenguer-Ruiz L; Gimenez-Martinez J; Palazón-Bru A; Sempere AP
    J Neurol; 2019 Oct; 266(10):2512-2517. PubMed ID: 31256279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A patient with relapsing-remitting multiple sclerosis who relapsed frequently and developed primary biliary cholangitis after pregnancy and discontinuation of fingolimod].
    Azami S; Konoeda F; Sato H
    Rinsho Shinkeigaku; 2021 Jan; 61(1):43-46. PubMed ID: 33328415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
    Tichá V; Kodým R; Počíková Z; Kadlecová P
    Clin Drug Investig; 2017 Feb; 37(2):175-186. PubMed ID: 27785735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors Predictive of Severe Multiple Sclerosis Disease Reactivation After Fingolimod Cessation.
    Uygunoglu U; Tutuncu M; Altintas A; Saip S; Siva A
    Neurologist; 2018 Jan; 23(1):12-16. PubMed ID: 29266038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical activity after fingolimod cessation: disease reactivation or rebound?
    Frau J; Sormani MP; Signori A; Realmuto S; Baroncini D; Annovazzi P; Signoriello E; Maniscalco GT; La Gioia S; Cordioli C; Frigeni B; Rasia S; Fenu G; Grasso R; Sartori A; Lanzillo R; Stromillo ML; Rossi S; Forci B; Cocco E;
    Eur J Neurol; 2018 Oct; 25(10):1270-1275. PubMed ID: 29851435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors associated with fingolimod rebound: A single center real-life experience.
    Goncuoglu C; Tuncer A; Bayraktar-Ekincioglu A; Ayvacioglu Cagan C; Acar-Ozen P; Cakan M; Karabulut E; Karabudak R
    Mult Scler Relat Disord; 2021 Nov; 56():103278. PubMed ID: 34655957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
    Zivadinov R; Medin J; Khan N; Korn JR; Bergsland N; Dwyer MG; Chitnis T; Naismith RT; Alvarez E; Kinkel P; Cohan S; Hunter SF; Silva D; Weinstock-Guttman B;
    J Neuroimaging; 2018 Jul; 28(4):399-405. PubMed ID: 29749661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different MRI patterns in MS worsening after stopping fingolimod.
    Lapucci C; Baroncini D; Cellerino M; Boffa G; Callegari I; Pardini M; Novi G; Sormani MP; Mancardi GL; Ghezzi A; Zaffaroni M; Uccelli A; Inglese M; Roccatagliata L
    Neurol Neuroimmunol Neuroinflamm; 2019 Jul; 6(4):e566. PubMed ID: 31086807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immune reconstitution inflammatory syndrome and rebound syndrome in multiple sclerosis patients who stopped disease modification therapy: current understanding and a case report].
    Belova AN; Rasteryaeva MV; Zhulina NI; Belova EM; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2. Vyp. 2):74-84. PubMed ID: 28617365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond conventional therapies: IVIG in treating severe fingolimod-rebound in a postpartum patient with MS.
    Tunç A; Akbaş AA; Bozkurt B; Oncel S
    BMJ Case Rep; 2024 Jul; 17(7):. PubMed ID: 39059796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.
    Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
    Front Immunol; 2018; 9():2669. PubMed ID: 30524432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination.
    Rolfes L; Pawlitzki M; Pfeuffer S; Thomas C; Schmidt-Chanasit J; Gross CC; Schulte-Mecklenbeck A; Wiendl H; Meuth SG; M Grauer O; Ruck T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.